Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 06

1666P - Lower virus neutralizing titers against SARS-CoV-2 Omicron strain after third dose BNT162b2 following primo-vaccination with ChAdOx1 versus BNT162b2 in cancer patients

Date

10 Sep 2022

Session

Poster session 06

Topics

Clinical Research;  Translational Research;  COVID-19 and Cancer

Tumour Site

Presenters

Yana Debie

Citation

Annals of Oncology (2022) 33 (suppl_7): S758-S771. 10.1016/annonc/annonc1078

Authors

Y. Debie1, J. Van Audenaerde1, T. Vandamme2, L. Croes3, L.M.N. Teuwen2, L. Verbruggen2, G. Vanhoutte2, E. Marcq1, D. Le Blon1, B. Peeters4, M.E. goossens5, K. Arien6, S. Anguille7, E. Smits1, C. Vulsteke3, E. Lion8, M. Peeters2, P.A. van Dam2

Author affiliations

  • 1 Center For Oncological Research (core), Integrated Personalized And Precision Oncology Network (ippon), University of Antwerp, 2610 - Wilrijk/BE
  • 2 Multidisciplinary Oncological Center Antwerp (moca), UZA - University Hospital Antwerp, 2650 - Edegem/BE
  • 3 Geintegreerd Kankercentrum Gent (ikg), AZ Maria Middelares, 9000 - Gent/BE
  • 4 Department Of Laboratory Medicine, Antwerp University Hospital, 2650 - Edegem/BE
  • 5 Sd Infectious Diseases In Humans, Service Immune Response, Sciensano, 1050 - Brussel/BE
  • 6 Virology Unit, Institute of Tropical Medicine Antwerp (ITM),, 2000 - Antwerpen/BE
  • 7 Division Of Hematology), UZA - University Hospital Antwerp, 2650 - Edegem/BE
  • 8 Laboratory Of Experimental Hematology (leh), Vaxinfectio, University of Antwerp, 2610 - Wilrijk/BE
More

Abstract 1666P

Background

Cancer patients display reduced humoral responses after initial COVID-19 vaccination. Although vaccination protects against severe COVID-19, T cell immunity is impaired in cancer patients. In recent studies, booster vaccines provide additional protection against SARS-CoV-2. However, more data is needed on different vaccination schedules. This prospective study compares BNT162b2 booster-vaccination after primo-vaccination with BNT162b2 (homologous) versus ChAdOx1 (heterologous) in cancer patients.

Methods

441 subjects (314 cancer patients and 127 healthy individuals) received a 3rd dose BNT162b2 (229 homologous vs 212 heterologous) 6-9 months after priming. Vaccine induced adverse events (AE) were captured up to 7 days after vaccination. Humoral immunity was assessed by SARS-CoV-2 anti-S1 IgG antibody levels and SARS-CoV-2 50% neutralization titers (NT50) for Wuhan and Omicron strains. Cellular immunity was examined by analyzing CD4 and CD8 T cell responses against SARS-CoV-2 specific S1 and S2 peptides. All assays were performed on blood samples collected 28 days after 3rd dose.

Results

Local AEs were more common after heterologous boosting, while no significant differences were seen for systemic AEs. SARS-CoV-2 anti-S1 IgG antibody levels did not differ significantly between homologous and heterologous boosted subjects (GMT 1755.90 BAU/ml [95% C) 1276.95-2414.48] vs 1495.82 BAU/ml (95% CI 1131.48-1977.46)). However, homologously boosted subjects show significantly higher NT50 values against Omicron. T cell responses were assessed by CD154 (CD40L) and CD137 expression on CD4 and CD8 T cells as general markers of antigen-specific stimulation. Here, no significant differences in T cell responses and cytokine levels of IFNγ, IL-2 and TNFα were observed between both boosting regimens.

Conclusions

Homologous and heterologous boosted patients elicit similar SARS-CoV-2 anti-S1 IgG antibody levels. Yet, heterologous boosted subjects report more local AEs and homologous boosted subjects show significantly higher NT50 values against Omicron. No difference between T cell responses in heterologous and homologous boosted cohorts was observed.

Clinical trial identification

EudraCT 2021-000300-38; EudraCT 2021-003573-58 EC/PMAL/2021.0110.

Editorial acknowledgement

Legal entity responsible for the study

Antwerp University Hospital.

Funding

Sciensano, Kom op Tegen Kanker.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.